Tumor‐derived Vimentin as a novel biomarker for distinct subtypes predicting adjuvant chemotherapy resistance and T‐cell‐inflamed phenotype in small cell lung cancer

Tumor‐derived Vimentin as a novel biomarker for distinct subtypes predicting adjuvant chemotherapy resistance and T‐cell‐inflamed phenotype in small cell lung cancer

Abstract Despite recent progress in subtype classification for small cell lung carcinoma (SCLC), little is known about the biomarker for triple‐negative (ASCL1, NEUROD1, and POU2F3 negative) tumors. The long‐term survival, adjuvant chemotherapy (ACT) response, and immune milieu in different SCLC sub...

Full description

Bibliographic Details
Main Authors: Chaoqiang Deng, Yue Wang, Fangqiu Fu, Di Li, Qiang Zheng, Yan Jin, Yuan Li, Haiquan Chen, Yang Zhang
Format: Article
Language:English
Published: Wiley 2023-10-01
Series:MedComm
Subjects:
chemotherapy
immune landscape
long‐term survival
molecular subtype
SCLC
Online Access:https://doi.org/10.1002/mco2.370

Internet

https://doi.org/10.1002/mco2.370

Similar Items